| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease |
|
Medicine details |
|
| Medicine name | voxelotor (Oxbryta®) |
| Formulation | oral |
| Reference number | 3619 |
| Indication | Treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide |
| Company | Global Blood Therapeutics Inc |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/10/2022 |
| NICE guidance | TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease |